WONDERLAB Joins Leading Experts at an Allergy Medicine Conference to Explore New Developments in Probiotics for Children with Allergies

From June 27 to 29, the 8th Academic Conference on Allergy Medicine, organized by the Allergy Medicine Committee of the Chinese Research Hospital Association, was held in Hangzhou. As an authoritative platform that has been repeatedly included in the China Association for Science and Technology’s Guidelines for Important Academic Conferences, the conference focused on “Allergy Medicine with an International Perspective and Chinese Characteristics” and provided in-depth interpretations of guidelines for the prevention and treatment of allergic diseases. Against the backdrop of increasingly standardized development in the probiotic industry, WONDERLAB, an industry benchmark for evidence-based research integrating scientific research and clinical practice, participated in the conference and discussed the latest global advances in allergy medicine with leading experts.

According to the China White Paper on the Epidemiology of Allergic Diseases, the current prevalence of allergic diseases in China has reached 30%–40%. As environmental and ecological conditions change, the incidence of allergic diseases among children has risen markedly; over the past decade, the incidence of allergic rhinitis, food allergies and other conditions in children has increased 2.3-fold.

Given the wide range of allergy-focused probiotic products on the market and the uneven clinical evidence supporting their strains, experts at the conference provided in-depth interpretations of clinical research on two core strains, offering an authoritative reference for evidence-based selection. Clinical results showed that Lacticaseibacillus paracasei GM080 was studied in 122 children with perennial allergic rhinitis: after 2 weeks of supplementation, sneezing frequency decreased significantly; at 4 weeks, nasal symptoms such as rhinorrhea and nasal itching improved markedly; at 8 weeks, nasal congestion eased; and at 12 weeks, levels of immune-protective factors in the body increased. In an 8-week intervention involving 53 patients with allergic rhinitis combined with asthma, Limosilactobacillus reuteri CCFM1040 significantly improved rhinitis symptoms, shortness of breath and quality of life. Its clinical value in improving allergies through dual immunomodulatory mechanisms provides robust evidence for the strain’s use in related probiotic products.

As a benchmark company for evidence-based R&D in China’s probiotic industry, WONDERLAB drives biotech innovation through clinical research and has built a full-chain evidence-based system extending from strain screening to multicenter trials. Experts at the event noted that clinical research on using a multi-strain probiotic formulation to improve allergies in children is also underway. Notably, WONDERLAB set up an “Evidence-Based Probiotics Experience Zone” at the conference, where it held in-depth discussions with attending experts, scholars and industry professionals.

WONDERLAB will continue to deepen its work in microbiological science and collaborate with academic experts on clinical research topics. Grounded in evidence-based medicine, it will advance the translation of laboratory findings into applications and provide an innovative pillar for building a system for allergy prevention and control with Chinese characteristics.